CMS Wants to Balance the Cost of Drugs Approved through the Accelerated Process and It Has an Idea!

CMS realizes that some drugs approved through the FDA’s accelerated-approval process won’t prove to be safe and effective in final analysis.  It wants to balance its payment for products that might not pan out in confirmatory trials by trying to make firms sprint, rather than crawl, to finalizing such studies.  How?  Well, we know that […]

Read More